Patrizia Cavazzoni

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial
    Patrizia Cavazzoni
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, 1 Corporate Plaza, DC 6314, Indianapolis, IN 46285, USA
    Eur Neuropsychopharmacol 13:81-5. 2003
  2. ncbi request reprint Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics
    Thomas A Hardy
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:405-8. 2006
  3. ncbi request reprint Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp
    Margaret Sowell
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Indiana 46285, USA
    J Clin Endocrinol Metab 88:5875-80. 2003
  4. ncbi request reprint Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia
    Alan Breier
    Lilly Research Laboratories, DC 2128, 1 Corporate Plaza, Indianapolis, IN 46285, USA
    Am J Psychiatry 162:1879-87. 2005
  5. ncbi request reprint Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications
    Patrizia Cavazzoni
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    Br J Psychiatry Suppl 47:S94-101. 2004
  6. ncbi request reprint Diabetes mellitus and antipsychotic treatment in the United Kingdom
    Christopher Carlson
    Eli Lilly and Company, Indianapolis, IN, USA
    Eur Neuropsychopharmacol 16:366-75. 2006
  7. ncbi request reprint A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects
    Malcolm Mitchell
    Lilly Research Centre, Eli Lilly and Co Ltd, Windlesham, Surrey, United Kingdom
    Clin Ther 28:881-92. 2006
  8. ncbi request reprint Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo
    Margaret O Sowell
    Lilly Research Laboratories, Eli Lilly and Co, Corporate Center, Drop Code 1758, Indianapolis, IN 46285, USA
    J Clin Endocrinol Metab 87:2918-23. 2002
  9. ncbi request reprint A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States
    John B Buse
    Diabetes Care Center and Division of General Medicine, University of North Carolina School of Medicine, 5039 Old Clinic Building, CB 7110, Chapel Hill, NC 27599 7110, USA
    J Clin Epidemiol 56:164-70. 2003
  10. ncbi request reprint A prospective study of the offspring of bipolar parents responsive and nonresponsive to lithium treatment
    Anne Duffy
    Department of Psychiatry, University of Ottawa, Royal Ottawa Hospital, Ottawa, Ontario, Canada
    J Clin Psychiatry 63:1171-8. 2002

Collaborators

Detail Information

Publications11

  1. ncbi request reprint Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial
    Patrizia Cavazzoni
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, 1 Corporate Plaza, DC 6314, Indianapolis, IN 46285, USA
    Eur Neuropsychopharmacol 13:81-5. 2003
    ..Nizatidine 300 mg b.i.d. may have an early transient effect in limiting the weight gain, but this potential early effect appeared to be diminished or eliminated by 16 weeks...
  2. ncbi request reprint Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics
    Thomas A Hardy
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:405-8. 2006
    ..Although interpretation of this study is limited by the cross-sectional study design, it provides additional insight concerning the relationship between antipsychotic use and plasma lipid parameters in this population...
  3. ncbi request reprint Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp
    Margaret Sowell
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Indiana 46285, USA
    J Clin Endocrinol Metab 88:5875-80. 2003
    ..In summary, this study did not demonstrate significant changes in insulin sensitivity in healthy subjects after 3 wk of treatment with olanzapine or risperidone...
  4. ncbi request reprint Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia
    Alan Breier
    Lilly Research Laboratories, DC 2128, 1 Corporate Plaza, Indianapolis, IN 46285, USA
    Am J Psychiatry 162:1879-87. 2005
    ..The efficacy and safety of olanzapine were compared with those of ziprasidone...
  5. ncbi request reprint Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications
    Patrizia Cavazzoni
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    Br J Psychiatry Suppl 47:S94-101. 2004
    ..In this retrospective analysis, we assessed the short-term risk of treatment-emergent diabetes (TED) among patients with schizophrenia during clinical trials of antipsychotic medications...
  6. ncbi request reprint Diabetes mellitus and antipsychotic treatment in the United Kingdom
    Christopher Carlson
    Eli Lilly and Company, Indianapolis, IN, USA
    Eur Neuropsychopharmacol 16:366-75. 2006
    ..This retrospective cohort study explored the UK General Practice Research Database (GPRD) to determine hazard ratios of diabetes for patients prescribed antipsychotics...
  7. ncbi request reprint A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects
    Malcolm Mitchell
    Lilly Research Centre, Eli Lilly and Co Ltd, Windlesham, Surrey, United Kingdom
    Clin Ther 28:881-92. 2006
    ..Prescription monitoring in the United States suggests that oral olanzapine is prescribed in doses that exceed the approved range of 5 to 20 mg/d...
  8. ncbi request reprint Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo
    Margaret O Sowell
    Lilly Research Laboratories, Eli Lilly and Co, Corporate Center, Drop Code 1758, Indianapolis, IN 46285, USA
    J Clin Endocrinol Metab 87:2918-23. 2002
    ..The results of this study do not support the hypothesis that olanzapine or risperidone directly impair pancreatic beta-cell function...
  9. ncbi request reprint A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States
    John B Buse
    Diabetes Care Center and Division of General Medicine, University of North Carolina School of Medicine, 5039 Old Clinic Building, CB 7110, Chapel Hill, NC 27599 7110, USA
    J Clin Epidemiol 56:164-70. 2003
    ..An increased risk of developing diabetes compared with the AdvancePCS general patient population was observed during treatment with conventional or atypical antipsychotics...
  10. ncbi request reprint A prospective study of the offspring of bipolar parents responsive and nonresponsive to lithium treatment
    Anne Duffy
    Department of Psychiatry, University of Ottawa, Royal Ottawa Hospital, Ottawa, Ontario, Canada
    J Clin Psychiatry 63:1171-8. 2002
    ..The aim of this study was to prospectively characterize the clinical course, including antecedent and comorbid conditions, among the offspring of 2 groups of bipolar parents divided on the basis of response to lithium...
  11. ncbi request reprint Is response to prophylactic lithium a familial trait?
    Paul Grof
    Department of Psychiatry, University of Ottawa, Ontario, Canada
    J Clin Psychiatry 63:942-7. 2002
    ..However, this recommendation has not been adequately substantiated in the literature. We tested the hypothesis that response to long-term lithium treatment is a familial trait...